2259. Reversal of antimicrobial consumption: long-term impact of COVID-19 pandemic

Abstract

Abstract Background The global decrease in antimicrobial consumption (AMC) in 2020 has been associated with the COVID-19 pandemic. However, it is not clear whether this downward trend will continue. Several reports, including ESAC-Net, have documented an increase in antimicrobial use after a decrease in antimicrobial consumption following the COVID-19 pandemic in some countries. The aim of this study is to examine the global trend in AMC following the emergence of COVID-19 in the long term. Methods After comparing the change rate of AMC in 67 countries’ using IQVIA MIDAS® monthly sales data of antimicrobials between 2019 and 2020 and between 2021 and 2022, changepoint detection was conducted in time-series data from November 2016 to October 2022. Additionally, we examined the impact of implementation and lifting of movement restriction in G7 countries by interrupted time-series analysis (ITSA). Results In the IQVIA MIDAS sales data, 65 among 67 countries have one or two changepoints (Table1). 59 among 65 countries experienced a decrease in AMC after the beginning of COVID-19 pandemic. However, 50 among 59 countries showed reversal increase trend of AMC in 2022 (Figure1). ITSA showed that implementation of movement restriction had negative impact on AMC in all G7 countries (Figure2). Table 1. Number of antimicrobial consumption changepoints after COVID-19 pandemic Figure 1. Change rate in monthly antimicrobial consumption in each country from 2019 to 2020 and 2021 to 2022, March-August Figure 2. Interrupted time series analysis of antimicrobial consumption data in G7 countries Conclusion The global decrease in AMC in 2020 may not be due to COVID-19 itself, but to non-pharmaceutical interventions such as movement restrictions. Human mobility may be one of the key determinants of antimicrobial use at the population level. Disclosures All Authors: No reported disclosures